FDA denies approval for Actavis hypertension treatment

By

Generic drug maker Actavis Plc said the U.S. health regulator denied an approval for its hypertension treatment, a fixed-dose combination of nebivolol and valsartan.

The company said it would review the U.S. Food and Drug Administration's complete response letter and decide on appropriate next steps.

The regulator issues a complete response letter when a new or generic treatment cannot be approved in its current form.

Actavis did not give any further details on the contents of the letter.

In a study, the drug combination was found more effective in reducing blood pressure in patients of hypertension, compared with independent doses of nebivolol and valsartan, Actavis said.

The company's shares closed at $254.20 on the New York Stock Exchange on Wednesday.

Tags
U.S., U.S. Food and Drug Administration
Join the Discussion
More News
Criminalizing Losses in Hindsight: The Government Overreaches in Prosecuting Shetty

Criminalizing Losses in Hindsight: The Government Overreaches in Prosecuting Shetty

Diddy

Diddy's Legal Troubles Pile Even Higher As Trial Quickly Approaches

Russell Brand

Russell Brand Attacks British Legal System in First Response to Rape Charges: 'The Law Has Become Kind of A Weapon'

Teen Facing Murder Charges Had Written About Wanting to Kill

Teen Facing Murder Charges Had Written About Wanting to Kill Her Mother in Her Diary: Police